Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UBEWB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2023232144A1ADC22
|
|||||
| Synonyms |
WO2023232144A1ADC22
Click to Show/Hide
|
|||||
| Organization |
CANWELL BIOTECH LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.33
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2025015586A1, ADC22, Payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site asparaginate random conjugation.
|
|||||
| Combination Type |
4- ((S)-2- ((S)-2- (6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (4- ((4-amino-2-butyl- 7- (dimethylphosphoryl)-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)carbamate
|
|||||